Study guide

3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor

Minnesota MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Minnesota MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & MN Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 MN Board, Licensure & Eligibility

4.1 Minnesota Board of Pharmacy Authority & Sources of Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & 1,600-Hour Experience

5 Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 HPSP, Impaired Practitioners & Mandatory Reporting

6 Technicians, Interns & Supervision

6.1 Technician Registration, Training & CE 6.2 Supervision Ratios (Statute 151.102 & Rule 6800.3850) 6.3 Intern Scope, Delegation & Certification of Accuracy

7 Prescription Authority & Validity

7.1 Who May Prescribe in Minnesota 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (Chapter 152 + Federal) 7.4 Refills, Partial Fills & Quantity Limits

8 Advanced MN Pharmacist Practice

8.1 Collaborative Practice Agreements & Medication Therapy Management 8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37) 8.3 Immunizations & Vaccine Administration 8.4 Drug Administration & Therapy Management

9 Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements (Rule 6800.0910) 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs (Rule 6800.2700)

10 MN PMP & Opioid Public-Health Laws

10.1 Minnesota PMP Overview, Reporting & Pharmacist Use 10.2 Naloxone Access, Steve’s Law & Opioid Antagonists 10.3 Legitimate Medical Purpose & Red Flags

11 Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Delivery & Work Conditions 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Centralized Processing & Automation

13 Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Minnesota Compounding Rules & Beyond-Use Dates

14 Test-Day Strategy & Final Review

14.1 When Minnesota Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor

Key Takeaways Explain This Topic AI

OBRA '90 created a federal Medicaid floor requiring prospective drug utilization review and an offer to counsel Medicaid outpatients, plus patient-profile and retrospective DUR infrastructure.

Prospective DUR screens therapy before dispensing for problems such as therapeutic duplication, drug-disease and drug-drug interactions, incorrect dose/duration, allergies, and clinical abuse/misuse.

Federal OBRA requires an active offer to counsel for covered Medicaid outpatient prescriptions; passive signs alone do not satisfy the counseling-offer concept tested on the MPJE.

Minnesota Rule 6800.0910 is stricter than the federal Medicaid-only floor: pharmacists personally initiate counseling on new prescriptions (and counsel on refills when judgment warrants), applying broadly in community practice.

On MN MPJE items, never stop at the federal floor if Minnesota imposes a higher counseling or DUR duty—prevailing Minnesota law controls the correct answer.

Last updated: July 2026

3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor

Minnesota MPJE focus: OBRA '90 is the federal floor for Medicaid prospective DUR and counseling offers. Minnesota Rule 6800.0910 is stricter —pharmacists personally initiate counseling on new prescriptions and counsel on refills when professional judgment warrants. If a question pits "Medicaid-only offer" against Minnesota counseling duties, choose Minnesota.

What OBRA '90 Changed

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) transformed community pharmacy from a pure product-hand-off model into a patient-safety model. Congress tied Medicaid funding to state pharmacy program requirements. The statute's pharmacy core (Social Security Act provisions implementing Medicaid DUR) established three interlocking pillars:

  • Prospective drug utilization review (ProDUR) before dispensing
  • Offer to counsel Medicaid outpatients about their therapy
  • Patient profiles and retrospective DUR systems run with state oversight

Although the federal statute's counseling mandate is written around Medicaid outpatient beneficiaries, almost every state board—including Minnesota—incorporated and often expanded these duties so they apply in ordinary retail practice. The MN MPJE therefore tests both (a) the federal OBRA structure and (b) Minnesota's stricter counseling rule.

Prospective DUR: Before the Patient Leaves

Prospective DUR is real-time review of a prescription before it is dispensed, using the patient profile and clinical screening tools. Software alerts help, but legal responsibility remains with the pharmacist . Alert fatigue is not a defense when a serious interaction or allergy is obvious from the profile.

Screening categories you must know

Federal Medicaid DUR regulations require screening that addresses problems such as:

  • Category What you look for Classic example
  • Therapeutic duplication Same drug or same class without justification Two systemic NSAIDs together
  • Drug-disease contraindications Therapy worsens a documented condition NSAID in advanced CKD
  • Drug-drug interactions Clinically significant combinations Warfarin + high-dose TMP-SMX without plan

Incorrect dosage or duration Dose too high/low or course too long/short Ketorolac beyond labeled duration limits

Drug-allergy interactions Prior hypersensitivity Amoxicillin after documented penicillin anaphylaxis

Clinical abuse or misuse Overuse, early refills, doctor shopping patterns Multiple early CII fills with red flags

Over/under-utilization Gaps or excess use relative to directions Chronic inhaler refill every 3 days

When a significant problem is identified, the pharmacist must resolve it using professional judgment: contact the prescriber, clarify with the patient, adjust therapy when authorized, refuse to dispense if necessary, and document the intervention. Ignoring a hard stop for speed or profit is exam-wrong and practice-wrong.

  • Prospective vs retrospective DUR
  • Prospective: individual patient, before this fill leaves the pharmacy

Retrospective: aggregate claims and patterns after dispensing, used by state DUR programs for education and outlier management

MPJE scenarios almost always test prospective pharmacist duties at the bench.

Federal Counseling Floor: The "Offer"

Under OBRA '90's Medicaid framework, the pharmacy must make an offer to counsel the outpatient (or caregiver) regarding the medication. Key federal-concept points:

The offer must be meaningful and active for in-person encounters—not merely a wall sign that says "Ask if you have questions."

The patient may refuse ; counseling is not forced after a clear refusal, but the offer itself is required when the statute/rule applies.

Only a pharmacist (or, where state law allows, a supervised intern ) may provide the clinical counseling content; technicians may facilitate logistics but must not give clinical advice.

For mail-order / delivery , an offer is typically made in writing with a toll-free number for pharmacist access.

Counseling content under OBRA-style standards commonly includes drug name and description, dosage form and route, directions and duration, special directions/precautions, common severe side effects and what to do, techniques for self-monitoring, storage, refill information, and action for a missed dose—tailored to the patient and therapy.

Minnesota Is Stricter: Rule 6800.0910

This is the highest-yield MN overlay in this chapter.

Topic Federal OBRA floor (exam framing) Minnesota application

Who is covered Written as a Medicaid outpatient requirement Minnesota practice standards apply counseling duties beyond Medicaid-only community fills

  • What is required Offer to counsel Pharmacist personally initiates counseling on new prescriptions
  • Refills Focus on new Rx offer under the federal floor Counsel on refills when professional judgment warrants

Who initiates Offer may be extended by designated personnel in many federal/state models Emphasis on pharmacist-initiated counseling for new Rxs under Rule 6800.0910

How to answer MN MPJE counseling items

If the stem is pure federal history ("What did OBRA '90 require of Medicaid programs?"), answer with ProDUR + counseling offer + profiles/retrospective DUR .

If the stem is a Minnesota community pharmacy new Rx handoff, apply Rule 6800.0910 : the pharmacist initiates counseling; do not rely on "Medicaid-only" or a passive sign.

If the stem involves a refill , look for language about judgment, therapy changes, or patient questions—Minnesota expects counseling when judgment warrants, not only on brand-new therapy.

If the stem is mail-order , remember written offers and phone access still matter; Minnesota telepharmacy/remote models still require real pharmacist availability for counseling (detailed in later operations sections).

Patient Profiles

OBRA-era practice requires maintaining patient profiles with enough information to perform DUR: demographics, history of drugs and devices, known allergies/reactions, and pharmacist comments. Incomplete profiles produce incomplete DUR. Minnesota recordkeeping and privacy rules (including HIPAA, next section) govern how those profiles are stored and shared.

Connecting DUR to Dispensing Red Flags

Prospective DUR is the operational home for legitimate medical purpose and corresponding-responsibility thinking even when the drug is not controlled. A profile that shows dangerous duplication or allergy is a stop-sign before labeling and bagging. Documentation of interventions protects the patient and creates the record Board inspectors and civil litigants look for.

Section Checkpoint

OBRA '90 = federal Medicaid floor: ProDUR + offer to counsel + profiles/retrospective DUR.

Seven screening families drive ProDUR questions.

MN Rule 6800.0910 > federal floor for new-Rx pharmacist-initiated counseling.

Resolve and document significant DUR hits; software does not replace the pharmacist.